3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Hepatocellular
8
Melanoma
4
Uveal Melanoma
3
Sarcoma
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasms
2
Mesothelioma, Malignant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable Hepatocellular Carcinoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Leiomyosarcoma
1
Ichthyosis, X-Linked
1
HER2 Negative Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
ADI PEG20
×
Clear all
NCT02709512
2023-10-04
ATOMIC
Polaris Group
Phase 2/3
Completed
249 enrolled
17 charts